Out-licensing a compound or partnering a platform? The data rooms that protect clinical data and IP, what partners expect to see, and indicative budgets.
Life sciences and IP licensing are core markets, and it pairs SOC 2 and ISO 27001 with document rights management, SSO and Q&A for partnering rounds that run many months.
SOC 2 and ISO 27001, Q&A, SSO and AI tools, with a deal-readiness approach that suits biotech companies preparing for repeat partnering or an eventual sale.
Redaction, SSO, an API and highly rated support, which helps when a large pharma partner's diligence team asks hundreds of technical questions.
Long experience with regulated industries and strong compliance credentials, a fit for larger licensing deals where the partner expects an established vendor.
In a licensing deal, the asset is information. A partner’s scientists are deciding whether your molecule, platform or device is worth a multi-year commitment, and the evidence lives in documents: preclinical studies, trial protocols, safety data, manufacturing records, patent filings. Lose control of those and you may have handed a competitor the very thing you meant to license.
That makes this one of the few scenarios where document protection matters more than speed.
Licensing and partnering rarely look like a classic auction. You might run several parallel conversations with different partners, each at its own stage, each with its own scientific, regulatory, clinical, CMC and business development reviewers.
Typical reviewers include:
Each group needs different folders, and each partner must stay invisible to the others.
Control documents after they leave the screen. Document rights management lets you block printing, prevent saving and expire access when a partnering conversation ends. For unpublished data, that is the difference between disclosure and leakage. ShareVault, Ansarada, iDeals and Intralinks all offer it in our data.
Keep a regulator-grade audit trail. Who opened which study, when, and for how long. If a dispute arises over what a partner knew before signing, the log is your evidence.
Separate tiers of disclosure. Non-confidential summary first, then a confidential tier under a CDA, then full diligence once a term sheet is agreed. Your permission groups should mirror those tiers.
Disclosure tiers in a licensing round
Handle patient-related data with care. Clinical documents may contain personal health information. Share de-identified data wherever possible. If US health information is involved, review the HHS guidance on de-identification under HIPAA with your counsel; for European trial data, the GDPR applies.
Decide what sits in the non-confidential, confidential and full diligence tiers, and which documents never leave your own systems.
Use top-level folders that match how partners review: corporate, IP, preclinical, clinical, regulatory, CMC, commercial.
Partner A in the confidential tier should not see Partner B, and should not see full diligence folders until you unlock them.
Turn on watermarking and view-only access for scientific data by default. Allow downloads only where a reviewer genuinely needs a file offline.
Route scientific, regulatory and IP questions to named experts, and require approval before answers go out.
Using a general file-sharing tool for unpublished data. Generic cloud storage is fine for collaboration, but most lack Q&A and some lack document rights management, which this scenario relies on.
Leaving rooms open after talks stall. Partnering conversations often go quiet rather than end. Set expiry dates on access and review the user list monthly.
Mixing partners in shared folders. It only takes one misconfigured group for a partner to see another’s term sheet or questions.
Licensing processes run longer than most M&A deals; six to twelve months is common, and multi-partner programmes can run longer. Nearly every provider on this shortlist quotes per deal, so ask for a price that covers a full year, includes storage growth as data packages expand, and allows several partner groups at no extra cost. Our pricing page explains the common models, and the security features guide covers what to test during a trial.
Full reviews: ShareVault, Ansarada, iDeals, Intralinks.
Out-licensing and in-licensing of compounds and technologies, co-development partnerships, fundraising for biotech companies, and M&A. The common thread is sharing unpublished scientific data and IP under tight control.
For unpublished clinical or preclinical data, yes. It lets you prevent printing and saving and revoke access to documents even after they have been opened.
Typically six to twelve months for a single partnering round, and longer for multi-partner programmes. Plan access expiry and archive export from the start.
Question 1 of 4
Finding your best match...
Your data room matches
Matches use our editorial ratings and published facts. How we rate